141 related articles for article (PubMed ID: 33054787)
1. Identification and in vivo characterization of a brain-penetrating nanobody.
Wouters Y; Jaspers T; De Strooper B; Dewilde M
Fluids Barriers CNS; 2020 Oct; 17(1):62. PubMed ID: 33054787
[TBL] [Abstract][Full Text] [Related]
2. Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody.
Esparza TJ; Su S; Francescutti CM; Rodionova E; Kim JH; Brody DL
Fluids Barriers CNS; 2023 Aug; 20(1):64. PubMed ID: 37620930
[TBL] [Abstract][Full Text] [Related]
3. Rapid Covalent Labeling of Membrane Proteins on Living Cells Using a Nanobody-Epitope Tag Pair.
Cabalteja CC; Sachdev S; Cheloha RW
Bioconjug Chem; 2022 Oct; 33(10):1867-1875. PubMed ID: 36107739
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.
Naderi S; Roshan R; Ghaderi H; Behdani M; Mahmoudi S; Habibi-Anbouhi M; Shokrgozar MA; Kazemi-Lomedasht F
Mol Immunol; 2020 Dec; 128():56-63. PubMed ID: 33070092
[TBL] [Abstract][Full Text] [Related]
5. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
Dong J; Huang B; Wang B; Titong A; Gallolu Kankanamalage S; Jia Z; Wright M; Parthasarathy P; Liu Y
Sci Rep; 2020 Oct; 10(1):17806. PubMed ID: 33082473
[TBL] [Abstract][Full Text] [Related]
6. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM; Gravel C; Lévesque M
J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
[TBL] [Abstract][Full Text] [Related]
7. Development of a Novel SPR Assay to Study CXCR4-Ligand Interactions.
Boonen A; Singh AK; Hout AV; Das K; Loy TV; Noppen S; Schols D
Biosensors (Basel); 2020 Oct; 10(10):. PubMed ID: 33096938
[TBL] [Abstract][Full Text] [Related]
8. Pro-neurotensin/neuromedin N and risk of ischemic stroke: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study.
Nicoli CD; Wettersten N; Judd SE; Howard G; Howard VJ; Struck J; Cushman M
Vasc Med; 2020 Dec; 25(6):534-540. PubMed ID: 33089749
[TBL] [Abstract][Full Text] [Related]
9. Non-Human Primate Blood-Brain Barrier and In Vitro Brain Endothelium: From Transcriptome to the Establishment of a New Model.
Chaves C; Do TM; Cegarra C; Roudières V; Tolou S; Thill G; Rocher C; Didier M; Lesuisse D
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33066641
[TBL] [Abstract][Full Text] [Related]
10. Single domain antibodies in the development of immunosensors for diagnostics.
Bastos-Soares EA; Sousa RMO; Gómez AF; Alfonso J; Kayano AM; Zanchi FB; Funes-Huacca ME; Stábeli RG; Soares AM; Pereira SS; Fernandes CFC
Int J Biol Macromol; 2020 Dec; 165(Pt B):2244-2252. PubMed ID: 33058975
[TBL] [Abstract][Full Text] [Related]
11. Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review.
Gao Y; Zhu J; Lu H
Drug Deliv Transl Res; 2021 Oct; 11(5):1818-1828. PubMed ID: 33155179
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P; Szary J; Rasmussen CLM; Demydchuk M; Northall L; Logan DB; Gauhar A; Thei L; Moos T; Walsh FS; Rutkowski JL
FASEB J; 2021 Feb; 35(2):e21172. PubMed ID: 33241587
[TBL] [Abstract][Full Text] [Related]
13. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Altunay B; Morgenroth A; Beheshti M; Vogg A; Wong NCL; Ting HH; Biersack HJ; Stickeler E; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1371-1389. PubMed ID: 33179151
[TBL] [Abstract][Full Text] [Related]
14. Protein Delivery by Peptide-Based Stealth Liposomes: A Biomolecular Insight into Enzyme Replacement Therapy.
Santi M; Finamore F; Cecchettini A; Santorelli FM; Doccini S; Rocchiccioli S; Signore G
Mol Pharm; 2020 Dec; 17(12):4510-4521. PubMed ID: 33112630
[TBL] [Abstract][Full Text] [Related]
15. Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.
Serneels L; T'Syen D; Perez-Benito L; Theys T; Holt MG; De Strooper B
Mol Neurodegener; 2020 Oct; 15(1):60. PubMed ID: 33076948
[TBL] [Abstract][Full Text] [Related]
16. Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
De Vlaeminck Y; Bonelli S; Awad RM; Dewilde M; Rizzolio S; Lecocq Q; Bolli E; Santos AR; Laoui D; Schoonooghe S; Tamagnone L; Goyvaerts C; Mazzone M; Breckpot K; Van Ginderachter JA
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266104
[TBL] [Abstract][Full Text] [Related]
17. Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.
Ruiz-López E; Schuhmacher AJ
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439797
[TBL] [Abstract][Full Text] [Related]
18. Applicability of cerebral open flow microperfusion and microdialysis to quantify a brain-penetrating nanobody in mice.
Custers ML; Wouters Y; Jaspers T; De Bundel D; Dewilde M; Van Eeckhaut A; Smolders I
Anal Chim Acta; 2021 Sep; 1178():338803. PubMed ID: 34482878
[TBL] [Abstract][Full Text] [Related]
19. VHHs as tools for therapeutic protein delivery to the central nervous system.
Wouters Y; Jaspers T; Rué L; Serneels L; De Strooper B; Dewilde M
Fluids Barriers CNS; 2022 Oct; 19(1):79. PubMed ID: 36192747
[TBL] [Abstract][Full Text] [Related]
20. Applications of nanobodies in brain diseases.
Zheng F; Pang Y; Li L; Pang Y; Zhang J; Wang X; Raes G
Front Immunol; 2022; 13():978513. PubMed ID: 36426363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
